Fate Therapeutics (FATE) Invested Capital (2012 - 2019)

Fate Therapeutics (FATE) has 8 years of Invested Capital data on file, last reported at $13.9 million in Q3 2019.

• Quarterly Invested Capital rose 326.84% year-over-year to $13.9 million in Q3 2019, while the trailing twelve-month figure through Jun 2020 was $13.9 million (down 7.67% YoY) and the FY2018 annual result came in at $2.4 million, changed N/A from the prior year.
• Invested Capital grew to $13.9 million in Q3 2019, from $5.4 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $13.9 million in Q3 2019 to a low of $758000.0 in Q1 2018.
• A 5-year average of $5.9 million and a median of $6.0 million in 2015 frame the typical range for Invested Capital.
• Annual changes were most pronounced in 2015 — Invested Capital surged 962.85% — and 2018, when it tumbled 90.12%.
• Tracing FATE's Invested Capital over 5 years: stood at $7.7 million in 2015, then climbed by 6.48% to $8.2 million in 2016, then retreated by 6.3% to $7.7 million in 2017, then slumped by 68.22% to $2.4 million in 2018, then jumped by 471.45% to $13.9 million in 2019.
• The last three Invested Capital figures came in at $13.9 million (Q3 2019), $5.4 million (Q2 2019), and $3.9 million (Q1 2019), per Business Quant data.